Comparing two immunotherapy drugs for limited-stage small cell lung cancer after chemo-radiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new immunotherapy drugs (QL1706 and QL1604) to see if they help keep limited-stage small cell lung cancer from coming back after you've finished chemo and radiation. The goal is to compare the two study drugs against each other to find a better way to extend your remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (cancer is only in one lung and nearby chest lymph nodes).
- You have completed 4 cycles of standard chemotherapy (cisplatin or carboplatin plus etoposide) together with radiation to the chest.
- After chemo and radiation, your scans show the cancer has shrunk or stayed the same (not grown).
- You do not have active autoimmune or inflammatory diseases, or a history of them.
- You do not have interstitial lung disease or active pneumonia (mild radiation-related lung irritation that did not need steroids is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, followed by radiation to the chest, for people with extensive-stage small cell lung cancer who have not been treated yet. The goal is to see if this approach can shrink the cancer and help people live longer.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.